Invitrogen

CD152 (CTLA-4) Monoclonal Antibody (9H10), Functional Grade, eBioscience™

CD152 (CTLA-4) Antibody in Flow Cytometry (Flow)

FIGURE: 1 / 3

CD152 (CTLA-4) Antibody (16-1521-82) in Flow

Oncology letters 2018 - Published figure using CD152 (CTLA-4) monoclonal antibody (Product # 16-1521-82) in Flow Cytometry

CD152 (CTLA-4) Antibody in Neutralization (Neu)

Product Image Gallery

Product Details

16-1521-82

Applications

Tested Dilution

Publications

Flow Cytometry (Flow)

0.5 µg/test

View 3 publications 3 publications

ELISA (ELISA)

View 1 publication 1 publication

Neutralization (Neu)

View 1 publication 1 publication

Functional Assay (Functional)

Assay-Dependent

View 6 publications 6 publications

Inhibition Assays (IA)

View 1 publication 1 publication

Product Specifications

Species Reactivity

Mouse

Published species

Mouse

Host/Isotype

Syrian hamster / IgG

Recommended Isotype Control

Syrian Hamster IgG Isotype Control, Functional Grade, eBioscience™

Class

Monoclonal

Type

Antibody

Clone

9H10

Conjugate

Functional Grade Functional Grade Functional Grade

Form

Liquid

Concentration

1 mg/mL

Purification

Affinity chromatography

Storage buffer

PBS, pH 7.2

Contains

no preservative

Storage conditions

4° C

Shipping conditions

Ambient (domestic); Wet ice (international)

RRID

AB_469075

Product Specific Information

Description: The 9H10 monoclonal antibody reacts with mouse CD152, also known as the cytotoxic T lymphocyte antigen-4 (CTLA-4). CTLA-4, a protein with structural similarities to CD28, is expressed on activated T cells and binds the B7 family members, CD80 (B7-1) and CD86 (B7-2), with higher affinity than CD28 does. CTLA-4 and CD28 appear to deliver opposing signals to T cells: while CD28 is a potent costimulator, CTLA-4 restricts the progression of T cells to an activated state by inhibiting IL-2 secretion and cellular proliferation. The cytoplasmic portion of CTLA-4 contains ER retention motifs, resulting in a large proportion of newly synthesized CTLA-4 in response to TCR signaling to be localized intracellularly.

Applications Reported: The 9H10 antibody has been reported for use in flow cytometric analysis. It has also been reported for use in in vitro functional studies.

Applications Tested: The 9H10 antibody has been tested by flow cytometric analysis of resting and Con A-stimulated mouse splenocytes. This can be used at less than or equal to 0.5 µg per test. A test is defined as the amount (µg) of antibody that will stain a cell sample in a final volume of 100 µL. Cell number should be determined empirically but can range from 10^5 to 10^8 cells/test. It is recommended that the antibody be carefully titrated for optimal performance in the assay of interest.

Furthermore, due to the intracellular localization of a large portion of CTLA-4, for complete detection it may be necessary to assess intracellular expression, in addition to surface expression of CTLA-4.

Storage and handling: Use in a sterile environment.

Filtration: 0.2 µm post-manufacturing filtered.

Purity: Greater than 90%, as determined by SDS-PAGE.

Endotoxin Level: Less than 0.001 ng/µg antibody, as determined by LAL assay.

Aggregation: Less than 10%, as determined by HPLC.

Target Information

CTLA4 (Cytotoxic T-Lymphocyte Antigen 4) is a CD28-family receptor expressed on mainly CD4+ T cells. It binds the same ligands as CD28 (CD80 and CD86 on B cells and dendritic cells), but with higher affinity than CD28. However, in contrast to CD28 which enhances cell function when bound at the same time as the T cell receptor, CTLA4 inhbits the T cell and prevents it from functioning. Intracellular CTLA4 is also found in regulatory T cells and may be important to their function.

For Research Use Only. Not for use in diagnostic procedures. Not for resale without express authorization.

Product References

Potential function of CTLA-4 in the tumourigenic capacity of melanoma stem cells.

Oncology letters

Zhang B,Dang J,Ba D,Wang C,Han J,Zheng F

16-1521 was used in Functional assays to demonstrate that melanoma cell-intrinsic cytotoxic T lymphocyte antigen-4 induces tumour cell proliferation in vitro and suppresses tumour cell apoptosis.

Thu Nov 01 00:00:00 EDT 2018

Potential function of CTLA-4 in the tumourigenic capacity of melanoma stem cells.

Oncology letters

Zhang B,Dang J,Ba D,Wang C,Han J,Zheng F

16-1521 was used in Functional assays to demonstrate that melanoma cell-intrinsic cytotoxic T lymphocyte antigen-4 induces tumour cell proliferation in vitro and suppresses tumour cell apoptosis.

Thu Nov 01 00:00:00 EDT 2018

CD1b-autoreactive T cells recognize phospholipid antigens and contribute to antitumor immunity against a CD1b⁺ T cell lymphoma.

Oncoimmunology

Bagchi S,Li S,Wang CR

Tue Jan 12 00:00:00 EST 2021

CD1b-autoreactive T cells recognize phospholipid antigens and contribute to antitumor immunity against a CD1b⁺ T cell lymphoma.

Oncoimmunology

Bagchi S,Li S,Wang CR

Tue Jan 12 00:00:00 EST 2021

CTLA-4 and PD-L1 checkpoint blockade enhances oncolytic measles virus therapy.

Molecular therapy : the journal of the American Society of Gene Therapy

Engeland CE,Grossardt C,Veinalde R,Bossow S,Lutz D,Kaufmann JK,Shevchenko I,Umansky V,Nettelbeck DM,Weichert W,Jäger D,von Kalle C,Ungerechts G

16-1521 was used in in vivo experiments to suggest rapid translation of combining immune checkpoint modulation with oncolytic viruses into clinical application.

Sat Nov 01 00:00:00 EDT 2014

Adenosine limits the therapeutic effectiveness of anti-CTLA4 mAb in a mouse melanoma model.

American journal of cancer research

Iannone R,Miele L,Maiolino P,Pinto A,Morello S

16-1521 was used in Functional assays to investigate the effectiveness of cytotoxic T lymphocyte-associated antigen 4 antibody in a murine model of melanoma.

Mon Mar 24 00:00:00 EDT 2014

Blockade of LFA-1 augments in vitro differentiation of antigen-induced Foxp3⁺ Treg cells.

Journal of immunological methods

Verhagen J,Wraith DC

16-1521 was used in Functional assays to identify factors that allow the generation of antigen-specific iTreg cells at higher purities.

Mon Dec 01 00:00:00 EST 2014

Targeting immune co-stimulatory effects of PD-L1 and PD-L2 might represent an effective therapeutic strategy in stroke.

Frontiers in cellular neuroscience

Bodhankar S,Chen Y,Lapato A,Vandenbark AA,Murphy SJ,Offner H

16-1521 was used in Flow cytometry/Cell sorting to investigate PD-L1 and PD-L2 expressing cell types that affect T-cell activation post stroke, and how these could be targeted therapeutically.

Tue Aug 26 00:00:00 EDT 2014

Radiotherapy-induced anti-tumor immunity contributes to the therapeutic efficacy of irradiation and can be augmented by CTLA-4 blockade in a mouse model.

PloS one

Yoshimoto Y,Suzuki Y,Mimura K,Ando K,Oike T,Sato H,Okonogi N,Maruyama T,Izawa S,Noda SE,Fujii H,Kono K,Nakano T

16-1521 was used in Flow cytometry/Cell sorting to indicate that tumor-specific immune responses play an important role in the therapeutic efficacy of irradiation.

Mon Jun 01 00:00:00 EDT 2015

Radiotherapy-induced anti-tumor immunity contributes to the therapeutic efficacy of irradiation and can be augmented by CTLA-4 blockade in a mouse model.

PloS one

Yoshimoto Y,Suzuki Y,Mimura K,Ando K,Oike T,Sato H,Okonogi N,Maruyama T,Izawa S,Noda SE,Fujii H,Kono K,Nakano T

16-1521 was used in Flow cytometry/Cell sorting to indicate that tumor-specific immune responses play an important role in the therapeutic efficacy of irradiation.

Mon Jun 01 00:00:00 EDT 2015

CTLA-4 blockade expands infiltrating T cells and inhibits cancer cell repopulation during the intervals of chemotherapy in murine mesothelioma.

Molecular cancer therapeutics

Wu L,Yun Z,Tagawa T,Rey-McIntyre K,de Perrot M

16-1521 was used in in vivo experiments to evaluate the impact of CTLA-4 blockade on the early stages of tumour development in a subcutaneous murine mesothelioma model.

Wed Aug 01 00:00:00 EDT 2012

Specific subsets of murine dendritic cells acquire potent T cell regulatory functions following CTLA4-mediated induction of indoleamine 2,3 dioxygenase.

International immunology

Mellor AL,Chandler P,Baban B,Hansen AM,Marshall B,Pihkala J,Waldmann H,Cobbold S,Adams E,Munn DH

16-1521 was used in Blocking experiments to suggest that IDO-competent DCs provide a regulatory bridge, mediated by CTLA4-B7 engagement, between certain regulatory T cell subsets and naive responder T cells.

Fri Oct 01 00:00:00 EDT 2004

Bioinformatics

Protein Aliases: CD152; CD152 antigen; CTLA-4; Cytotoxic T-lymphocyte protein 4; Cytotoxic T-lymphocyte-associated antigen 4; ICOS

View more View less

Gene Aliases: Cd152; Ctla-4; Ctla4; Ly-56

View more View less

UniProt ID: (Mouse) P09793

View more View less

Entrez Gene ID: (Mouse) 12477

View more View less

Function(s)

immunoglobulin receptor superfamily

Process(es)

immune system process immune response cellular response to DNA damage stimulus negative regulation of B cell proliferation negative regulation of T cell proliferation positive regulation of apoptotic process negative regulation of regulatory T cell differentiation negative regulation of immune response B cell receptor signaling pathway

Performance Guarantee

If an Invitrogen™ antibody doesn't perform as described on our website or datasheet,we'll replace the product at no cost to you, or provide you with a credit for a future purchase.*

Learn more

CD152 (CTLA-4) Monoclonal Antibody (9H10), Functional Grade, eBioscience™

CD152 (CTLA-4) Antibody (16-1521-82) in Flow

Product Details

16-1521-82

Flow Cytometry (Flow)

ELISA (ELISA)

Neutralization (Neu)

Functional Assay (Functional)

Inhibition Assays (IA)

Species Reactivity

Published species

Host/Isotype

Recommended Isotype Control

Class

Type

Clone

Conjugate

Form

Concentration

Purification

Storage buffer

Contains

Storage conditions

Shipping conditions

RRID

Product Specific Information

Target Information

Bioinformatics

Performance Guarantee

We're here to help

Your items have has been added!